ReviewJournal of clinical hypertension (Greenwich, Conn.)2011
Angiotensin receptor blockers: pharmacology, efficacy, and safety.
Review in Journal of clinical hypertension (Greenwich, Conn.), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 97 citations in OpenAlex.
- Combining angiotensin receptor blockers with chlorthalidone or hydrochlorothiazide - which is the better alternative? A meta-analysis.Systematic reviews · 2020Pooled it
- Guideline
- 24-Hour blood pressure response to lower dose (30 mg) fimasartan in Korean patients with mild to moderate essential hypertension.The Korean journal of internal medicine · 2017Trial
- The Impact of Azilsartan Medoxomil Treatment (Capsule Formulation) at Doses Ranging From 10 to 80 mg: Significant, Rapid Reductions in Clinic Diastolic and Systolic Blood Pressure.Journal of clinical hypertension (Greenwich, Conn.) · 2017Trial
- Azilsartan in Patients With Mild to Moderate Hypertension Using Clinic and Ambulatory Blood Pressure Measurements.Journal of clinical hypertension (Greenwich, Conn.) · 2017Trial
- Comparative Effectiveness of ACE Inhibitors and Angiotensin Receptor Blockers for Cardiovascular Disease Prevention in People Living with HIV and Hypertension.medRxiv : the preprint server for health sciences · 2026Article
- Repurposing the angiotensin II receptor blocker valsartan to inhibit penicillin-binding protein 3 and its mutants inFrontiers in bioinformatics · 2026Article
- Cancer therapy-induced cardiotoxicity: mechanisms and mitigations.Heart failure reviews · 2025Review
- Article
- A Rare Case of Valsartan-Induced Angioedema.Cureus · 2025Article
- A perspective on small molecules targeting the renin-angiotensin-aldosterone system and their utility in cardiovascular diseases: exploring the structural insights for rational drug discovery and development.RSC medicinal chemistry · 2025Review
- Fifty-Four Tablets Too Many: A Case Report of Amlodipine and Losartan Overdose.Clinical case reports · 2025Article
- Review
- Genetic Deletion of β-Arrestin 2 From the Subfornical Organ and Other Periventricular Nuclei in the Brain Alters Fluid Homeostasis and Blood Pressure.Hypertension (Dallas, Tex. : 1979) · 2024Article
- Lower Incidence of Hypoglycemia With Angiotensin Receptor Blocker Versus ACE Inhibitor Therapy in People With or Without Diabetes.Clinical diabetes : a publication of the American Diabetes Association · 2024Article
- The Renin Angiotensin System as a Therapeutic Target in Traumatic Brain Injury.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2023Review
- Rifampicin-induced hypertensive urgency: eyes see what the mind knows.BMJ case reports · 2023Article
- Role of Angiotensin II in Cardiovascular Diseases: Introducing Bisartans as a Novel Therapy for Coronavirus 2019.Biomolecules · 2023Review
- Twenty-Three-Year Trends in the Use of Potentially Nephrotoxic Drugs in Denmark.Clinical epidemiology · 2023Article
- Effectiveness and Safety of a Fixed-Dose Combination of Valsartan and Rosuvastatin (RovatitanDrug design, development and therapy · 2023Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
key points and practical recommendations• The angiotensin receptor blockers are highly effective antihypertensive agents that are also particularly well tolerated. • There are no major differences in efficacy or other clinical characteristics among older drugs in this class, although some of the newer agents may more effectively reduce blood pressure than older agents. • Major randomized clinical trials have demonstrated that angiotensin receptor blockers provide significant outcomes benefits in conditions such as diabetic nephropathy, chronic heart failure or heart failure following myocardial infarction, hypertension with left ventricular hypertrophy and in patients whose histories of previous events or complicated diabetes puts them at high cardiovascular risk. • In treating hypertension, angiotensin receptor blockers can be used as first-line therapy or added at later stages of treatment titration. • These drugs are very effective in combination with thiazide diuretics or calcium channel blockers and there are several single-pill, fixed-dose combinations of angiotensin receptor blockers with hydrochlorothiazide, amlodipine, or aliskiren. These combinations can be given as initial therapy (where appropriate) or later in the course of treatment. Three-drug combinations (angiotensin receptor blocker plus amlodipine plus hydrochlorothiazide and angiotensin receptor blocker plus aliskiren plus hydrochlorothiazide) are also available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.